Xpovio Combo Significantly Extends Survival in RRMM, Trial Results Show
Adding Xpovio (selinexor) to Velcade (bortezomib)…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreAdding Xpovio (selinexor) to Velcade (bortezomib)…
With an emphasis on the ability of patients and…
In recognition of Rare Disease Day Feb. 29,…
The U.S. Food and Drug Administration (FDA) has…
Myeloma is a form of blood cancer that…
One of the most common genomic defects in multiple…